Behind The News - 21 August 2012

CONCERN about a link between statin use and diabetes arose earlier this year when the FDA changed the label on the drugs in the US to warn of a small increased risk.

Now an analysis of the JUPITER trial, funded by AstraZeneca, has found the benefits outweigh the risk even among those most likely to develop the disease.

Diabetes was most likely to occur in those who already had one or more risk factors, particularly impaired fasting glucose, the study results showed in a findings which should reassure GPs.

Professor Anthony Keech
Deputy director, NHMRC Clinical Trials Centre
“THERE is clear evidence from this study that there is net benefit over the risk of diabetes, in terms of major complications of cardiovascular disease, including heart attacks, strokes and death.